We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

30 hedge funds and large institutions have $138M invested in Clearside Biomedical in 2016 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

161% more capital invested

Capital invested by funds: $52.8M → $138M (+$84.8M)

100% more funds holding

Funds holding: 15 → 30 (+15)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
30
Holders Change
+15
Holders Change %
+100%
% of All Funds
0.8%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
20
Increased
1
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.71M
2
BFA
BlackRock Fund Advisors
California
+$1.8M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.76M
4
State Street
State Street
Massachusetts
+$462K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$344K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.05M
2
RSCM
Rock Springs Capital Management
Maryland
-$1.05M
3
SFM
Sphera Funds Management
Israel
-$603K
4
IHM
Iguana Healthcare Management
New York
-$526K
5
Millennium Management
Millennium Management
New York
-$485K

CLSD Hedge Fund Activity: Q3 2016 in Review

30 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2016, worth a combined $138M — up 161% from $52.8M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new CLSD positions and 5 closed out — a net gain of 15 holders — while 1 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $2.71M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.05M sold.

  • 30 institutional investors held Clearside Biomedical (CLSD) as of Q3 2016, up from 15 in Q2 2016.
  • Funds reported $138M of Clearside Biomedical stock for Q3 2016, up 161% quarter-over-quarter.
  • 20 funds opened new Clearside Biomedical positions in Q3 2016 and 5 closed out, a net change of +15 holders.
  • The largest Clearside Biomedical buyer in Q3 2016 was Vanguard Group, an estimated $2.71M added.
  • The largest Clearside Biomedical seller in Q3 2016 was Alyeska Investment Group, an estimated $1.05M sold.

Based on aggregated 13F filings for Q3 2016.